Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05281523 | Completed Phase 3 Results DMC FDA Drug

• 2 other identifiers: 2180792021-005055-36
• Study Type: interventional
• Target: 264
• Locations: 9 countries
• Sites: 84

Brief Summary

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).

Conditions

Nasal Polyps

Keywords

Depemokimab; GSK3511294; Chronic rhinosinusitis; Verbal response scale; Asthma Control Questionnaire; Lund Mackay computed tomography; Nasal polyps score; Nasal endoscopy

Outcome Measures

Primary Outcomes (2)

• Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read)

  Total endoscopic nasal polyps (NP) score evaluated the size and extent of nasal polyps via endoscopy. The assessments were performed by central video image recordings of nasal endoscopy. The right and left nostrils were scored from 0 to 4 (0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle concha; 2 = Polyps reaching below the lower border of the middle turbinate; 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha; and 4 = Large polyps causing complete obstruction of the inferior meatus). The scores were graded based on NP size, recorded as sum of the right and left nostril scores and ranges from 0 (no polyps) to 8 (large polyps), calculated by summing the scores \[0 to 4\] in each nostril; with higher scores indicating worse status. Baseline was defined as Day 1 value. Change from Baseline = Post-baseline value minus Baseline value.

  Baseline (Day 1) and at Week 52

• Change From Baseline in Mean Nasal Obstruction Score Using Verbal Response Scale From Weeks 49 Through to Week 52

  This endpoint evaluated the change from baseline in the mean nasal obstruction score using a Verbal Response Scale (VRS) from Week 49 through to Week 52. Participants used a VRS to rate nasal obstruction severity, with scores averaged over the specified period to assess treatment impact on nasal obstruction symptoms. Participants were asked to indicate the severity of nasal obstruction at their worst over the last 24 hours using a 4-point VRS, with options of no symptoms, mild symptoms, moderate symptoms, and severe symptoms. This was scored on a scale ranging from 0 (no symptoms) to 3 (severe symptoms), with higher scores indicating worse status. Baseline was defined as the average score from 28 days of eDiary data collected prior to Day 1. Change from Baseline = Post-baseline value minus Baseline value.

  Baseline (Day 1) and from Week 49 to Week 52

Secondary Outcomes (10)

• Change From Baseline in Mean Symptom Score for Rhinorrhea (Runny Nose) Using Verbal Response Scale From Week 49 Through to Week 52

  Baseline (Day 1) and from Week 49 to Week 52

• Change From Baseline in Mean Symptom Score for Loss of Smell From Week 49 Through to Week 52

  Baseline (Day 1) and from Week 49 to Week 52

• Change From Baseline in Lund Mackay (LMK) Computed Tomography (CT) Score at Week 52

  Baseline (Day 1) and at Week 52

• Change From Baseline in Sino-nasal Outcome Test (SNOT)-22 Total Score at Week 52

  Baseline (Day 1) and at Week 52

• Change From Baseline in Mean Nasal Obstruction Score From Week 21 Through to Week 24

  Baseline (Day 1) and from Week 21 to Week 24

Study Arms (2)

Depemokimab

EXPERIMENTAL

Participants received a 100 milligram (mg) dose of depemokimab subcutaneous (SC) injection once every 26 weeks (week 0 and week 26) over a treatment period of 52-weeks. Participants were to be maintained on their existing baseline maintenance Chronic rhinosinusitis with nasal polyps (CRSwNP) standard of care (SOC) treatment throughout the study.

Biological: Depemokimab (GSK3511294)

Placebo

PLACEBO COMPARATOR

Participants received placebo SC injection once every 26 weeks (week 0 and week 26) over a treatment period of 52-weeks. Participants were to be maintained on their existing baseline maintenance CRSwNP SOC treatment throughout the study.

Drug: Placebo

Interventions

Depemokimab (GSK3511294) BIOLOGICAL

Depemokimab (GSK3511294) was administered using a pre-filled syringe.

Depemokimab

Placebo DRUG

Placebo was administered as normal saline using a pre-filled syringe.

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants with 18 years of age and older inclusive, at the time of signing the informed consent.
• Endoscopic bilateral NP score of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity) assessed by the investigator.
• Participants who have had at least one of the following at Visit 1: Previous nasal surgery for the removal of NP; Have used at least three consecutive days of systemic corticosteroids in the previous 2 years for the treatment of NP; Medically unsuitable or intolerant to systemic corticosteroid.
• Participants (except for those in Japan) must be on daily treatment with intranasal corticosteroids (INCS) (including intranasal liquid steroid wash/douching) for at least 8 weeks prior to screening.
• Participants presenting with severe NP symptoms defined as symptoms of nasal congestion/blockade/obstruction with moderate or severe severity and loss of smell or rhinorrhea (runny nose) based on clinical assessment by the investigator.
• Presence of symptoms of chronic rhinosinusitis as described by at least 2 different symptoms for at least 12 weeks prior to Visit 1, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip), plus facial pain/pressure and/or reduction or loss of smell.
• Male or eligible female participants

You may not qualify if:

• As a result of medical interview, physical examination, or screening investigation the physician responsible considers the participant unfit for the study.
• Cystic fibrosis.
• Antrochoanal polyps.
• Nasal cavity tumor (malignant or benign)
• Fungal rhinosinusitis
• Severe nasal septal deviation occluding one nostril preventing full assessment of nasal polyps in both nostrils.
• Participants who had a sino-nasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of nasal polyp score.
• Acute sinusitis or upper respiratory tract infection (URTI) at screening or in 2 weeks prior to screening.
• Ongoing rhinitis medicamentosa (rebound or chemical induced rhinitis).
• Participants who have had an asthma exacerbation requiring admission to hospital within 4 weeks of Screening.
• Participants who have undergone any intranasal and/or sinus surgery (for example polypectomy, balloon dilatation or nasal stent insertion) within 6 months prior to Visit 1; nasal biopsy prior to Visit 1 for diagnostic purposes only is excepted.
• Participants where NP surgery is contraindicated in the opinion of the Investigator.
• Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) eosinophilic granulomatosis with polyangiitis (EGPA) (formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis.
• Participants with a known, pre-existing parasitic infestation within 6 months prior to Visit 1.
• A known immunodeficiency (e.g. human immunodeficiency virus (HIV), other than that explained by the use of corticosteroids (CSs) taken as therapy for asthma.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (84)

GSK Investigational Site

Tucson, Arizona, 85724, United States

Location

GSK Investigational Site

Roseville, California, 95661, United States

Location

GSK Investigational Site

New Haven, Connecticut, 06520, United States

Location

GSK Investigational Site

Hialeah, Florida, 33012, United States

Location

GSK Investigational Site

Baltimore, Maryland, 21287, United States

Location

GSK Investigational Site

Grand Rapids, Michigan, 55446, United States

Location

GSK Investigational Site

Columbia, Missouri, 65212, United States

Location

GSK Investigational Site

Oklahoma City, Oklahoma, 73120, United States

Location

GSK Investigational Site

Fort Worth, Texas, 76109, United States

Location

GSK Investigational Site

McAllen, Texas, 78503, United States

Location

GSK Investigational Site

McKinney, Texas, 75070, United States

Location

GSK Investigational Site

San Antonio, Texas, 78258, United States

Location

GSK Investigational Site

Norfolk, Virginia, 23507, United States

Location

GSK Investigational Site

Morgantown, West Virginia, 26506-9200, United States

Location

GSK Investigational Site

Changsha, 410013, China

Location

GSK Investigational Site

Chengdu, 610041, China

Location

GSK Investigational Site

Guangzhou, 510000, China

Location

GSK Investigational Site

Hangzhou, 310000, China

Location

GSK Investigational Site

Nanjing, 210009, China

Location

GSK Investigational Site

Shanghai, 200003, China

Location

GSK Investigational Site

Shanghai, 200031, China

Location

GSK Investigational Site

Suzhou, China

Location

GSK Investigational Site

Wuhan, 430060, China

Location

GSK Investigational Site

Xiamen, 361004, China

Location

GSK Investigational Site

Zhongshan, 528400, China

Location

GSK Investigational Site

Zibo Shandong Province, 255036, China

Location

GSK Investigational Site

Bologna, 40139, Italy

Location

GSK Investigational Site

Catania, 95123, Italy

Location

GSK Investigational Site

Milan, 20132, Italy

Location

GSK Investigational Site

Napoli, 80131, Italy

Location

GSK Investigational Site

Padua, 35100, Italy

Location

GSK Investigational Site

Pisa, Italy

Location

GSK Investigational Site

Roma, 00128, Italy

Location

GSK Investigational Site

Roma, 00168, Italy

Location

GSK Investigational Site

Rozzano MI, 20089, Italy

Location

GSK Investigational Site

Varese, 21100, Italy

Location

GSK Investigational Site

Aichi, 471-8513, Japan

Location

GSK Investigational Site

Chiba, 262-0015, Japan

Location

GSK Investigational Site

Chiba, 272-0143, Japan

Location

GSK Investigational Site

Gunma, 373-8585, Japan

Location

GSK Investigational Site

Hyōgo, 650-0047, Japan

Location

GSK Investigational Site

Hyōgo, 665-0827, Japan

Location

GSK Investigational Site

Ibaraki, 309-1793, Japan

Location

GSK Investigational Site

Kanagawa, 211-8533, Japan

Location

GSK Investigational Site

Nagano, 395-8505, Japan

Location

GSK Investigational Site

Shiga, 525-8585, Japan

Location

GSK Investigational Site

Shizuoka, 420-0853, Japan

Location

GSK Investigational Site

Tokyo, 142-8666, Japan

Location

GSK Investigational Site

?Od?, 90-153, Poland

Location

GSK Investigational Site

Gdansk, 80-214, Poland

Location

GSK Investigational Site

Katowice, 40-611, Poland

Location

GSK Investigational Site

Krakow, 30-033, Poland

Location

GSK Investigational Site

Krakow, 31-513, Poland

Location

GSK Investigational Site

Lubin, 59-300, Poland

Location

GSK Investigational Site

Nadarzyn, 05-830, Poland

Location

GSK Investigational Site

Poznan, 60-355, Poland

Location

GSK Investigational Site

Strzelce Opolskie, 47-100, Poland

Location

GSK Investigational Site

Brasov, 500091, Romania

Location

GSK Investigational Site

Brasov, 500283, Romania

Location

GSK Investigational Site

Bucharest, 014146, Romania

Location

GSK Investigational Site

Bucharest, 014452, Romania

Location

GSK Investigational Site

Cluj-Napoca, 400349, Romania

Location

GSK Investigational Site

Timișoara, 300643, Romania

Location

GSK Investigational Site

Barcelona, 08022, Spain

Location

GSK Investigational Site

Barcelona, 08036, Spain

Location

GSK Investigational Site

Barcelona, 08041, Spain

Location

GSK Investigational Site

Barcelona, 08907, Spain

Location

GSK Investigational Site

Jerez de la Frontera, 11407, Spain

Location

GSK Investigational Site

Madrid, 28034, Spain

Location

GSK Investigational Site

Madrid, 28040, Spain

Location

GSK Investigational Site

Madrid, 28041, Spain

Location

GSK Investigational Site

Pamplona, 31008, Spain

Location

GSK Investigational Site

Santander, 39008, Spain

Location

GSK Investigational Site

Seville, 41009, Spain

Location

GSK Investigational Site

Valladolid, 47005, Spain

Location

GSK Investigational Site

Zaragoza, 50009, Spain

Location

GSK Investigational Site

Gothenburg, SE-413 45, Sweden

Location

GSK Investigational Site

Lund, SE-221 85, Sweden

Location

GSK Investigational Site

Stockholm, SE-114 86, Sweden

Location

GSK Investigational Site

Stockholm, SE-171 76, Sweden

Location

GSK Investigational Site

Ankara, 06230, Turkey (Türkiye)

Location

GSK Investigational Site

CapaIstanbul, 34093, Turkey (Türkiye)

Location

GSK Investigational Site

Izmir, 35330, Turkey (Türkiye)

Location

GSK Investigational Site

Tekirdağ, 59100, Turkey (Türkiye)

Location

Related Publications (3)

• Gevaert P, Cornet M, Mullol J, De Corso E, Keles Turel N, Desrosiers M, et al. . ANCHOR-1/-2 primary data including pooled analysis ms. Lancet. PMID: 40037388 DOI: 10.1016/S0140-6736(25)00197-7

  BACKGROUND

• Jackson DJ, Bourdin A, Blackorby A, Leslie A, Vichiendilokkul A, Howarth P, Karkoszka N, Fujieda S, Cornet M. Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2. Adv Ther. 2025 Dec 29. doi: 10.1007/s12325-025-03457-4. Online ahead of print.

  PMID: 41461999 DERIVED

• Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, Maspero J, Fujieda S, Zhang L, Sousa AR, Woods SJ, Davis AM, Schalkwijk S, Edwards D, Ranganathan P, Follows R, Marshall C, Han JK; ANCHOR-1 and ANCHOR-2 trial investigators. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet. 2025 Mar 15;405(10482):911-926. doi: 10.1016/S0140-6736(25)00197-7. Epub 2025 Mar 1.

  PMID: 40037388 DERIVED

MeSH Terms

Conditions

Nasal Polyps

Condition Hierarchy (Ancestors)

Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Polyps; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

GSKClinicalSupportHD@gsk.com

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Masking Details: This will be a double-blind study.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Participants will receive either depemokimab (GSK3511294) or placebo during the study.

Study Record Dates

• First Submitted: March 7, 2022
• First Posted: March 16, 2022
• Study Start: April 18, 2022
• Primary Completion: July 12, 2024
• Study Completion: August 6, 2024
• Last Updated: September 9, 2025
• Results First Posted: September 9, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
• Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Locations

JP (12); IT (10); CN (12); ES (13); TU (4); US (14); RO (6); PL (9); SE (4)